Epiomic Epidemiology Series: Behcet's Disease Forecast in 12 Major Markets 2016-2026

February 2016 | 60 pages | ID: EF2779FFB11EN
Black Swan Analysis limited

Abstracts

Behçet's disease (BD), also known as Silk Road Disease or Adamantiades-Behçet’s Disease, is a rare disease classified amongst a group of disorders termed “vasculitides”. The pathophysiology is thought to be autoimmune, linked to the HLA-B5/51 antigen. As a multisystem disease, clinical manifestations can involve nearly all systems of the body. The manifestations are self-limiting but recurrent and thus the majority of BD is characterized by a relapsing-remitting pattern.

This report provides the current prevalent population for Behcet’s disease across 12 Major Markets (USA, France, Germany, Italy, Spain, UK, Japan, Sweden, Turkey, China, Saudi Arabia and Egypt) split by gender and 5-year age cohort. Along with the current prevalence, the report also contains a disease overview of the risk factors, disease diagnosis and prognosis along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several of the main symptoms and co-morbidities of Behcet’s disease have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities for Behcet’s disease include:

• Skin involvement with or without Erythema Nodosum
• Genital ulcers
• Eye involvement with or without Uveitis
• Arthritis
• CNS involvement
• Vascular involvement

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world class sources that deliver the most up to date information from patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

• Able to quantify patient populations in global Behcet’s disease’s market to target the development of future products, pricing strategies and launch plans.
• Gain further insight into the prevalence of the subdivided types of Behcet’s disease and identify patient segments with high potential.
• Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
• Provide a level of understanding on the impact from specific co-morbid conditions on Behcet’s disease’s prevalent population.
• Identify sub-populations within Behcet’s disease which require treatment.
• Gain an understanding of the specific markets that have the largest number of Behcet’s disease patients.

Contents

Introduction
Cause of the Disease
Risk Factors & Prevention
Diagnosis of the Disease
Variation by Geography/Ethnicity
Disease Prognosis & Clinical Course
Key Co-morbid Conditions /Features Associated with the Disease
Methodology for Quantification of Patient Numbers
Top-Line Prevalence for Behcet’s Disease
Antigens and Pathergy in Bechet’s Disease Patients
Clinical Features of Bechet’s Disease Patients
  Skin Manifestations
  Ocular Manifestations
  Joint Manifestations
  CNS Manifestations
  Vascular Manifestations
  Cardiac Manifestations
  Gastrointestinal Manifestations
Abbreviations used in the Report
Other Black Swan Analysis Publications
Black Swan Analysis Online Patient-Based Databases
Patient-Based Offering
Online Pricing Data and Platforms
References
Appendix

List Of Tables

LIST OF TABLES

International Study Group guidelines for diagnosis
The ICBD criteria
Prevalence of Behçet’s Disease, total
Prevalence of Behçet’s Disease, males
Prevalence of Behçet’s Disease, females
BD patients that are HLA-B5/51 positive, total patients
BD patients with positive Pathergy test, total patients
BD patients with erythema nodosum, total patients
BD patients with folliculitis, total patients
BD patients with papulopustular lesions, total patients
BD patients with genital ulcers, total patients
BD patients with uveitis, total patients
BD patients with hypopyon iritis, total patients
BD patients with retinitis, total patients
BD patients with visual loss and blindness, total patients
BD patients with arthritis, total patients
Neurological involvement in BD, total patients
Course of the neurological involvement in BD, total patients
Acute neurological with single episode, total patients
Acute neurological with relapsing-remitting pattern, total patients
Chronic neurological, primary progressive, total patients
Chronic neurological, progressive with further relapses, total patients
Cerebral haemorrhage in BD patients with neurological involvement, total patients
Vascular involvement in BD, total patients
DVT in BD, total patients
Superficial thrombophlebitis in BD, total patients
Cardiac involvement in BD, total patients
Gastrointestinal (GI) involvement in BD, total patients
Bowel perforation in BD patients with GI involvement, total patients
Abbreviations and acronyms used in the report
USA Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
USA Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
France Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
France Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
Germany Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
Germany Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
Italy Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
Italy Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
Spain Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
Spain Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
United Kingdom Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
United Kingdom Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
Sweden Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
Sweden Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
Turkey Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
Turkey Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
Japan Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
Japan Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
China Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
China Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
Saudi Arabia Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
Saudi Arabia Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)
Egypt Prevalence of Behcet’s disease by 5-yr age cohort, males (000s)
Egypt Prevalence of Behcet’s disease by 5-yr age cohort, females (000s)